Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Clinical trial NCT05669807 · UNKNOWN
Trial details
- NCT number
- NCT05669807
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-01
- Primary completion
- 2023-11-01
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.